Recent Developments of Target Based Coumarin Derivatives as Potential Anticancer Agents.
Coumarin
cancer
multidrug-resistant
specific targets
synthetic strategies
tubulin protein
Journal
Mini reviews in medicinal chemistry
ISSN: 1875-5607
Titre abrégé: Mini Rev Med Chem
Pays: Netherlands
ID NLM: 101094212
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
11
2019
revised:
18
01
2020
accepted:
23
01
2020
pubmed:
11
5
2020
medline:
8
6
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
Cancer is the second life-threatening disease worldwide, and it resulted in around 9.6 million deaths globally in 2018. The multidrug-resistant cancers and non-selectivity create an urge for the development of novel anticancer drugs with a diverse mechanism of action. Coumarin is one of the most widely used scaffolds for the development of highly effective anticancer agents. It has versatile anticancer profiles with diverse mechanisms to inhibit tumor progression. The facile synthetic strategies are also favoured for target-based coumarin derivatives. Structural Activity Relationship (SAR) studies determine anticancer potentials with minimal side effects through the substitution pattern of coumarin. A number of coumarin derivatives have been developed against the Galectin-1 (Gal-1), Carbonic anhydrases (CAs), Tubulin protein, and other essential targets for the treatment in cancer therapy. Therefore, in this review, we have mainly focused on different target based coumarin derivatives, and synthetic strategies.
Identifiants
pubmed: 32386492
pii: MRMC-EPUB-106480
doi: 10.2174/1389557520666200510000718
doi:
Substances chimiques
Antineoplastic Agents
0
Coumarins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1754-1766Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.